Overview

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine if the use of sugammadex (compared with neostigmine) reduces the rate of postoperative pulmonary complications (PPCs).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Northern Sydney Anaesthesia Research Institute
Collaborators:
Merck Sharp & Dohme Corp.
Northern Sydney and Central Coast Area Health Service
Treatments:
Glycopyrrolate
Neostigmine
Criteria
Inclusion Criteria:

- age >18

- patients presenting for non-cardiac surgery

- planned operative time of over 1 hour

- plan to be intubated and to receive muscle relaxants for their surgery

- plan to stay at least one night in hospital

Exclusion Criteria:

- Previous recruitment to the trial

- Hypersensitivity to any of the study drugs

- Patient refusal

- Cognitive Impairment, or language proficiency leading to inability to complete QoR-15
questionnaire

- Body Mass Index (BMI) >40

- Planned postoperative intubation and ventilation

- Liver failure with Child-Pugh class B/C

- Renal failure with either regular peritoneal or haemodialysis or serum creatinine
>140mcgmol/L

- Women lactating, pregnant or of childbearing potential who are not willing to avoid
pregnancy during the study